Sol-Gel Technologies (SLGL) Stock Forecast & Price Target

Sol-Gel Technologies is attractive because SGT-610 targets a severe, underserved Gorlin syndrome population where patients can develop dozens or even hundreds of basal cell carcinomas and face repeated, costly surgeries, yet there is no approved therapy to prevent new lesions. The company’s pivotal Phase 3 trial enrolled 113 patients, with 102 completing the study, and management believes the late-2026 readout could support FDA review in 1H27 and a potential late-2027 approval, while end-1Q26 cash and marketable securities of about $52.8M should help fund development and submission activities. The opportunity is reinforced by thousands of identified U.S. patients, potential rare-disease pricing around $170,000 per year, added IP protection to 2044, and royalty growth from TWYNEO and EPSOLAY partnerships that may reach about $10M annually by 2031.

Sol-Gel Technologies is facing a fundamentally weak risk-reward profile because SGT-610’s Phase 3 is essentially a rerun of PellePharm’s prior failed study, which missed statistical significance in 2021 with p=0.73. The new trial relies on a retrospective efficacy signal from a small PTCH1+/high-burden subgroup, yet the underlying endpoint is noisy and event rates in vehicle patients were already low, making replication uncertain and commercial differentiation hard even if the study eventually succeeds. With only about $5M paid upfront for the asset in 2023 and a 9% discontinuation rate reported in 2Q26, the stock remains exposed to execution, reimbursement, and launch risk without clear evidence of durable value creation.